Chemical Namebezlotoxumab
Dosage FormInjection (intravenous; 1000 ml/40 mL)
Drug ClassMonoclonal antibodies
CompanyMerck & Co.
Approval Year2016


  • To reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.
Last updated on 10/26/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zinplava (bezlotoxumab) Prescribing Information2016Merck Sharp & Dohme Corp.